Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Inclusion Criteria:

* Joined the study voluntarily and signed informed consent form;
* Age 18-75 years; both genders
* Esophageal squamous cell carcinoma confirmed by pathology.
* No radiotherapy, chemotherapy or other treatments prior to enrollment
* Locally advanced esophageal squamous cell carcinoma (T1N1-3M0, T2-4NxM0, TxNxM1 (supraclavicular lymph node metastasis only) (AJCC 8th)
* Use of an effective contraceptive for adults to prevent pregnancy.
* No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function. No immunodeficiency.
* WBC ≥ 3.5\*109/L, Hemoglobin ≥ 9 g/dL, Neutrophils ≥ 1·5\*109/L, Platelet count ≥ 100\*109/L, ALAT and ASAT \< 2·5 \* ULN, TBIL \< 1·5 \* ULN, and Creatinine \< 1·5 \*ULN.
* ECOG 0-2.
* Life expectancy of more than 3 months.
* Agreement of PET/CT accessment at 25-28 radiotherapy fraction.

Exclusion Criteria:

* Total radiotherapy dose cannot reach 61.2Gy/34Fx in the condition of the nomal tissue dose complying to the standard criteria.
* Esophageal perforation, or hematemesis.
* History of radiotherapy or chemotherapy for esophageal cancer.
* History of surgery within 28 days before Day 1.
* History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years).
* Participation in other interventional clinical trials within 30 days.
* Pregnant or breast-feeding women or fertile patients who refused to use contraceptives.
* Drug addiction, alcoholism or AIDS.
* Uncontrolled seizures or psychiatric disorders.
* Any other condition which in the investigator's opinion would not make the patient a good candidate for the clinical trial.